查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954311

免疫细胞工程市场分析及预测（至2035年）：依类型、产品类型、服务、技术、应用、最终用户、製程、组件、功能及设备划分

Immune Cell Engineering Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Component, Functionality, Equipment
出版日期: | 出版商: Global Insight Services | 英文 305 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，免疫细胞工程市场规模将从2024年的41亿美元成长至313亿美元，复合年增长率约23%。免疫细胞工程市场涵盖用于改造免疫细胞以增强其治疗效果的技术和调查方法，包括基因编辑、细胞培养优化以及用于治疗癌症和自体免疫疾病的临床试验项目日益增多，也推动了该市场的发展。

免疫细胞工程市场正迅速扩张，这主要得益于细胞疗法和基因工程技术的进步。 T细胞工程领域由于其在个人化癌症疗法开发中的核心作用，展现出最高的成长速度。特别是CAR-T疗法，因其在治疗骨髓恶性肿瘤的成功而处于领先地位。 NK细胞工程紧随其后，在肿瘤学和感染疾病治疗方面均展现出巨大的潜力。这些经过基因工程改造的免疫细胞因其能够选择性地靶向并清除病变细胞而备受关注。基因编辑技术，特别是CRISPR-Cas9技术，对于提高免疫细胞工程的精准性和疗效至关重要。这一细分领域正吸引大量的投资和研究关注。此外，递送系统的进步，例如病毒载体和非病毒载体，对于克服基因转移相关的挑战至关重要。生物技术公司与学术机构之间日益密切的合作，旨在加速治疗方法创新，这也推动了市场的发展。

市场区隔
按类型 T细胞工程、B细胞工程、NK细胞工程、巨噬细胞工程、树突细胞工程、干细胞工程
产品 细胞株、试剂及试剂盒、设备、软体
服务 细胞治疗服务、基因编辑服务、客製化开发服务、咨询服务
科技 CRISPR、TALEN、锌指核酸酶、睡美人转座子、病毒载体、非病毒方法
应用领域 癌症免疫疗法、自体免疫疾病、感染疾病、再生医学、移植
最终用户 生技公司、製药公司、研究机构、医院和诊所
过程 体外工程、体内工程
成分 载体，质体
功能 基因敲除、基因敲入、基因调控
装置 生物反应器、细胞分选器

免疫细胞工程市场正经历市场份额、定价策略和产品创新方面的动态变化。主要企业正优先推出新产品以获得竞争优势。定价趋势受到技术进步和策略联盟的影响，从而提高了产品的可近性和可负担性。该市场以多元化的产品组合为特征，新兴企业正凭藉创新且经济高效的解决方案挑战现有企业。从区域来看，北美处于市场发展的前沿，而亚太地区由于生物技术投资的增加，正在迅速追赶。从竞争格局来看，市场较为分散，成熟企业和灵活的Start-Ups都在争夺主导。法规结构，尤其是在北美和欧洲，对塑造市场动态至关重要，严格的指导方针确保了产品的有效性和安全性。企业正在利用监管方面的洞察来简化产品核可并优化打入市场策略。竞争基准分析显示，企业正专注于策略联盟和研发投资以保持竞争优势。市场数据凸显了个人化医疗的发展趋势，这主要得益于基因编辑技术的进步，预计将推动市场成长。

主要趋势和驱动因素：

受基因工程和生物技术进步的推动，免疫细胞工程市场正经历强劲成长。其中一个关键趋势是CRISPR技术的整合，这项技术彻底革新了免疫细胞修饰的精准性和效率。这项创新使得开发更有效的癌症和自体免疫疾病治疗方法成为可能，显着改善了患者的治疗效果。另一个关键趋势是生物製药公司与学术机构之间合作的日益密切。这些伙伴关係正在加速研发进程，推动新型治疗方法的快速商业化。个人化医疗的兴起也是重要的驱动因素，免疫细胞工程在设计针对个别患者特征的治疗方法方面发挥关键作用。此外，慢性病盛行率的不断上升也推动了对创新治疗方案的需求。随着全球医疗系统优先发展先进疗法，免疫细胞工程市场预计将显着扩张。专注于可扩展且经济高效的生产方法的公司有望获得竞争优势。此外，监管支援和优惠的报销政策正在促进市场准入和扩张，为行业相关人员提供了盈利的机会。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • T细胞工程
    • B细胞工程
    • NK细胞工程
    • 巨噬细胞工程
    • 树突状细胞工程
    • 干细胞工程
  • 市场规模及预测：依产品划分
    • 细胞株
    • 试剂和试剂盒
    • 装置
    • 软体
  • 市场规模及预测：依服务划分
    • 细胞治疗服务
    • 基因编辑服务
    • 客製化开发服务
    • 咨询服务
  • 市场规模及预测：依技术划分
    • CRISPR
    • TALENs
    • 锌指核酸酶
    • 睡美人转座子
    • 病毒载体
    • 非病毒方法
  • 市场规模及预测：依应用领域划分
    • 癌症免疫疗法
    • 自体免疫疾病
    • 感染疾病
    • 再生医学
    • 移植
  • 市场规模及预测：依最终用户划分
    • 生技公司
    • 製药公司
    • 研究所
    • 医院和诊所
  • 市场规模及预测：依製程划分
    • 体外工程
    • 体内工程
  • 市场规模及预测：依组件划分
    • 向量
    • 质体
  • 市场规模及预测：依功能划分
    • 基因敲除
    • 基因敲入
    • 基因调控
  • 市场规模及预测：依设备划分
    • 生物反应器
    • 细胞分选装置

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Sangamo Therapeutics
  • Adaptimmune Therapeutics
  • Cellectis
  • Kiadis Pharma
  • Fate Therapeutics
  • Immatics Biotechnologies
  • Atara Biotherapeutics
  • Allogene Therapeutics
  • Poseida Therapeutics
  • Arcellx
  • Gritstone Oncology
  • TCR2 Therapeutics
  • Rubius Therapeutics
  • Bellicum Pharmaceuticals
  • Autolus Therapeutics
  • Glycostem Therapeutics
  • Celyad Oncology
  • Marker Therapeutics
  • Sorrento Therapeutics
  • Iovance Biotherapeutics

第九章：关于我们

简介目录
Product Code: GIS26627

Immune Cell Engineering Market is anticipated to expand from $4.1 billion in 2024 to $31.3 billion by 2034, growing at a CAGR of approximately 23%. The Immune Cell Engineering Market encompasses technologies and methodologies for modifying immune cells to enhance their therapeutic efficacy. This includes gene editing, cell culture optimization, and delivery systems aimed at treating diseases such as cancer and autoimmune disorders. Advances in CRISPR and CAR-T cell therapies are propelling growth, with a focus on precision medicine and personalized treatments. The market is driven by increasing investment in biotechnology and a growing pipeline of clinical trials seeking to harness the body's immune system to combat complex diseases.

The Immune Cell Engineering Market is expanding rapidly, fueled by advancements in cellular therapies and genetic engineering technologies. The T-cell engineering segment is the top performer, driven by its pivotal role in developing personalized cancer treatments. CAR-T therapies, specifically, are at the forefront due to their success in treating hematological malignancies. The NK cell engineering segment follows closely, as it offers promising potential in both oncology and infectious disease applications. These engineered immune cells are gaining traction for their ability to target and eliminate diseased cells selectively. Gene editing technologies, particularly CRISPR-Cas9, are instrumental in enhancing the precision and efficacy of immune cell engineering. This sub-segment is witnessing substantial investment and research focus. Furthermore, advancements in delivery systems, such as viral vectors and non-viral methods, are critical in overcoming challenges associated with gene transfer. The market is poised for growth with increasing collaborations between biotech firms and academic institutions, aiming to accelerate therapeutic innovation.

Market Segmentation
TypeT-Cell Engineering, B-Cell Engineering, NK-Cell Engineering, Macrophage Engineering, Dendritic Cell Engineering, Stem Cell Engineering
ProductCell Lines, Reagents and Kits, Instruments, Software
ServicesCell Therapy Services, Gene Editing Services, Custom Development Services, Consultation Services
TechnologyCRISPR, TALENs, Zinc Finger Nucleases, Sleeping Beauty Transposon, Viral Vectors, Non-Viral Methods
ApplicationCancer Immunotherapy, Autoimmune Disorders, Infectious Diseases, Regenerative Medicine, Transplantation
End UserBiotechnology Companies, Pharmaceutical Companies, Research Institutes, Hospitals and Clinics
ProcessEx Vivo Engineering, In Vivo Engineering
ComponentVectors, Plasmids
FunctionalityGene Knockout, Gene Knock-In, Gene Regulation
EquipmentBioreactors, Cell Sorters

The Immune Cell Engineering Market is witnessing dynamic shifts in market share, pricing strategies, and product innovations. Leading companies are prioritizing novel product launches to capture competitive advantage. Pricing trends are influenced by technological advancements and strategic partnerships, which are enhancing product accessibility and affordability. The market is characterized by a diverse range of offerings, with emerging players challenging established entities through innovative, cost-effective solutions. Geographically, North America remains at the forefront of market developments, with Asia-Pacific regions rapidly catching up due to increased investments in biotechnology. In terms of competition, the market is fragmented with both established giants and nimble startups vying for dominance. Regulatory frameworks, particularly in North America and Europe, are pivotal in shaping market dynamics, with stringent guidelines ensuring product efficacy and safety. Companies are leveraging regulatory insights to streamline product approvals and enhance market entry strategies. Competitive benchmarking reveals a focus on strategic alliances and R&D investments to maintain a competitive edge. Market data indicates a trend towards personalized medicine, driven by advancements in gene editing technologies, which are expected to propel market growth.

Geographical Overview:

The Immune Cell Engineering Market is witnessing notable growth across various regions, each presenting unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in biotechnology research. The presence of major biotech firms and innovative startups further propels the region's market dominance. Europe follows closely, with robust government support for research and development in cellular therapies enhancing market growth. The region's strong regulatory framework and emphasis on precision medicine contribute to its appeal. In Asia Pacific, the market is expanding rapidly, bolstered by increasing healthcare investments and a burgeoning biotech sector. Countries like China and Japan are emerging as key players, with significant advancements in genetic engineering technologies. Latin America and the Middle East & Africa are also witnessing growth. Brazil and Israel are notable emerging markets, driven by rising investments in healthcare innovation and supportive governmental policies. These regions offer lucrative opportunities for market expansion and collaboration.

Global tariffs and geopolitical tensions are significantly influencing the Immune Cell Engineering Market, particularly in East Asia. Japan and South Korea are navigating US-China trade tensions by enhancing domestic biotech capabilities and diversifying supply chains. China's strategy focuses on self-reliance, investing heavily in indigenous biotech innovations to mitigate export restrictions. Taiwan, a key player in biotech manufacturing, faces geopolitical risks but remains vital due to its advanced capabilities. The global Immune Cell Engineering Market is experiencing robust growth, driven by rising demand for personalized medicine and advancements in gene editing technologies. By 2035, the market is poised for substantial expansion, contingent on geopolitical stability and resilient supply chains. Middle East conflicts could indirectly affect the market by influencing global energy prices, impacting operational costs.

Key Trends and Drivers:

The Immune Cell Engineering Market is experiencing robust growth, driven by advances in genetic engineering and biotechnology. Key trends include the integration of CRISPR technology, which is revolutionizing the precision and efficiency of immune cell modifications. This innovation is enabling the development of more effective therapies for cancer and autoimmune diseases, significantly enhancing patient outcomes. Another major trend is the increasing collaboration between biopharmaceutical companies and academic institutions. These partnerships are accelerating research and development efforts, leading to faster commercialization of novel therapies. The rise of personalized medicine is also a crucial driver, with immune cell engineering playing a pivotal role in tailoring treatments to individual patient profiles. Additionally, the growing prevalence of chronic diseases is fueling demand for innovative therapeutic solutions. As healthcare systems globally prioritize advanced treatments, the immune cell engineering market is poised for substantial expansion. Companies focusing on scalable and cost-effective production methods are likely to gain a competitive advantage. Furthermore, regulatory support and favorable reimbursement policies are facilitating market entry and expansion, providing lucrative opportunities for industry stakeholders.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Functionality
  • 2.10 Key Market Highlights by Equipment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 T-Cell Engineering
    • 4.1.2 B-Cell Engineering
    • 4.1.3 NK-Cell Engineering
    • 4.1.4 Macrophage Engineering
    • 4.1.5 Dendritic Cell Engineering
    • 4.1.6 Stem Cell Engineering
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cell Lines
    • 4.2.2 Reagents and Kits
    • 4.2.3 Instruments
    • 4.2.4 Software
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Cell Therapy Services
    • 4.3.2 Gene Editing Services
    • 4.3.3 Custom Development Services
    • 4.3.4 Consultation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR
    • 4.4.2 TALENs
    • 4.4.3 Zinc Finger Nucleases
    • 4.4.4 Sleeping Beauty Transposon
    • 4.4.5 Viral Vectors
    • 4.4.6 Non-Viral Methods
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Cancer Immunotherapy
    • 4.5.2 Autoimmune Disorders
    • 4.5.3 Infectious Diseases
    • 4.5.4 Regenerative Medicine
    • 4.5.5 Transplantation
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biotechnology Companies
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Hospitals and Clinics
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Ex Vivo Engineering
    • 4.7.2 In Vivo Engineering
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Vectors
    • 4.8.2 Plasmids
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Gene Knockout
    • 4.9.2 Gene Knock-In
    • 4.9.3 Gene Regulation
  • 4.10 Market Size & Forecast by Equipment (2020-2035)
    • 4.10.1 Bioreactors
    • 4.10.2 Cell Sorters

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Component
      • 5.2.1.9 Functionality
      • 5.2.1.10 Equipment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Component
      • 5.2.2.9 Functionality
      • 5.2.2.10 Equipment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Component
      • 5.2.3.9 Functionality
      • 5.2.3.10 Equipment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Component
      • 5.3.1.9 Functionality
      • 5.3.1.10 Equipment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Component
      • 5.3.2.9 Functionality
      • 5.3.2.10 Equipment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Component
      • 5.3.3.9 Functionality
      • 5.3.3.10 Equipment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Component
      • 5.4.1.9 Functionality
      • 5.4.1.10 Equipment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Component
      • 5.4.2.9 Functionality
      • 5.4.2.10 Equipment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Component
      • 5.4.3.9 Functionality
      • 5.4.3.10 Equipment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Component
      • 5.4.4.9 Functionality
      • 5.4.4.10 Equipment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Component
      • 5.4.5.9 Functionality
      • 5.4.5.10 Equipment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Component
      • 5.4.6.9 Functionality
      • 5.4.6.10 Equipment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Component
      • 5.4.7.9 Functionality
      • 5.4.7.10 Equipment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Component
      • 5.5.1.9 Functionality
      • 5.5.1.10 Equipment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Component
      • 5.5.2.9 Functionality
      • 5.5.2.10 Equipment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Component
      • 5.5.3.9 Functionality
      • 5.5.3.10 Equipment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Component
      • 5.5.4.9 Functionality
      • 5.5.4.10 Equipment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Component
      • 5.5.5.9 Functionality
      • 5.5.5.10 Equipment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Component
      • 5.5.6.9 Functionality
      • 5.5.6.10 Equipment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Component
      • 5.6.1.9 Functionality
      • 5.6.1.10 Equipment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Component
      • 5.6.2.9 Functionality
      • 5.6.2.10 Equipment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Component
      • 5.6.3.9 Functionality
      • 5.6.3.10 Equipment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Component
      • 5.6.4.9 Functionality
      • 5.6.4.10 Equipment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Component
      • 5.6.5.9 Functionality
      • 5.6.5.10 Equipment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Sangamo Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Adaptimmune Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Cellectis
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Kiadis Pharma
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Fate Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Immatics Biotechnologies
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Atara Biotherapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Allogene Therapeutics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Poseida Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Arcellx
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Gritstone Oncology
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 TCR2 Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Rubius Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Bellicum Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Autolus Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Glycostem Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Celyad Oncology
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Marker Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Sorrento Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Iovance Biotherapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us